CE-STAND aims to address three areas under-represented in research: chronic, cervical, and autonomic dysfunction. It is both significant and highly impactful, as treating autonomic dysfunction could substantially improve function and quality of life (QoL) in chronic cervical SCI patients.
Spinal cord injury (SCI) affects over 18,000 individuals annually, leading to significant motor and autonomic dysfunctions that reduce quality of life (QoL). Epidural spinal cord stimulation (eSCS) has shown potential in restoring function in chronic individuals with SCI. However, research on cervical, and autonomic dysfunction-related SCI remains limited. This study will assess the safety and efficacy of eSCS in improving autonomic and volitional functions, as well as truncal stability, bowel, bladder, and sexual function, and overall QoL. The study is a Phase I/II trial in which participants will serve as their own controls. The Abbott Eterna epidural stimulator system will be implanted, and assessments will occur every three months. The study will be conducted over a period of four years. A total of 36 participants will be enrolled and followed for one year. Bayesian Optimization will be used to determine the most effective stimulation settings, with 15 settings programmed at the end of each visit. FDA and UMN IRB approvals have been secured for the study. Interim reports will be made available through peer-reviewed journals, conference presentations, and clinical network reporting. CE-STAND seeks to advance SCI treatment by expanding eSCS applications in chronic cervical SCI, improving patient outcomes, and reducing healthcare costs.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
36
Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead
University of Minnesota
Minneapolis, Minnesota, United States
RECRUITINGSafety of epidural spinal cord stimulator in chronic cervical patients
Incidence of adverse events (AEs) and serious adverse events (SAEs) including hypotension, other hemodynamic instability, infection, bleeding, significant pain, spasticity, or cerebrospinal fluid leak.
Time frame: 1 year
Changes in blood pressure
Measured on tilt table testing. Both systolic and diastolic pressure will be assessed
Time frame: 1 year
Changes in heart rate
Measured on tilt table testing
Time frame: 1 year
Cognitive function
Measured using N-back testing
Time frame: 1 year
Cerebral blood flow
Measured using transcranial doppler
Time frame: 1 year
Muscle Sympathetic Nerve Activities (MSNA)
Microneurolography
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.